The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Pfizer
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen; Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Leurquin Mediolanum (Inst); Lilly (Inst); MedImmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Ipsen; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Roche
First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.
 
Jae-Lyun Lee
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - Alteogen; Bristol-Myers Squibb; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Marek Ziobro
No Relationships to Disclose
 
Cristina Suarez
No Relationships to Disclose
 
Przemyslaw Langiewitz
No Relationships to Disclose
 
Vsevolod Borisovich Matveev
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen
 
Pawel Wiechno
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Merck; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Rustem Gafanov
No Relationships to Disclose
 
Piotr Tomczak
No Relationships to Disclose
 
Frédéric Pouliot
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Amgen BioPharama; Bayer; Janssen; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Sanofi (Inst)
Expert Testimony - Amgen; Astellas Pharma; Bayer; Sanofi
Travel, Accommodations, Expenses - Bayer; Sanofi
 
Frede Donskov
Research Funding - Ipsen (Inst); Pfizer (Inst)
 
Boris Alekseev
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; ICON Clinical Research; Janssen; Merck; Pfizer; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Sang Joon Shin
No Relationships to Disclose
 
Georg A. Bjarnason
Stock and Other Ownership Interests - Merck
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Xiaoqi Du
Employment - Merck
 
Rodolfo F. Perini
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Karla Rodriguez-Lopez
Employment - Karyopharm Therapeutics; Merck
Leadership - Karyopharm Therapeutics; Merck
Stock and Other Ownership Interests - Karyopharm Therapeutics; Merck
Honoraria - Karyopharm Therapeutics; Merck
Research Funding - Karyopharm Therapeutics; Merck
Travel, Accommodations, Expenses - Karyopharm Therapeutics; Merck
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Michael B. Atkins
Honoraria - Merck
Consulting or Advisory Role - Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Exelixis; Fathom Biotechnology; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; Oncolys BioPharma; Pfizer; Pneuma Respiratory; Pyxis; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)